Main takeaway: The company will review the resumption of dividends in FY26, after they were suspended in February following its $902m capital raise.
Ryman Healthcare has kicked the can down the road on the potential resumption of dividends by two years.
The company suspended making distributions to shareholders followings its $902 million capital raise in February, saying it was not suitable to raise money on one hand and give it back with
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
